Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2011 3
2012 3
2013 5
2014 11
2015 8
2016 14
2017 23
2018 31
2019 25
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Implementation and utilization of genetic testing in personalized medicine.
Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA. Abul-Husn NS, et al. Pharmgenomics Pers Med. 2014 Aug 13;7:227-40. doi: 10.2147/PGPM.S48887. eCollection 2014. Pharmgenomics Pers Med. 2014. PMID: 25206309 Free PMC article. Review.
This germline genetic risk, in conjunction with other clinical, family, and demographic variables, are the key components of the personalized medicine paradigm, which aims to apply personal genomic and other relevant data into a patient's clinic …
This germline genetic risk, in conjunction with other clinical, family, and demographic variables, are the key components of the p
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.
van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. van der Wouden CH, et al. Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Clin Pharmacol Ther. 2017. PMID: 28027596 Clinical Trial.
Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. ...The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the Euro …
Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of …
Implementation of personalized medicine in Central-Eastern Europe: pitfalls and potentials based on citizen's attitude.
Balicza P, Terebessy A, Grosz Z, Varga NA, Gal A, Fekete BA, Molnar MJ. Balicza P, et al. EPMA J. 2018 Feb 9;9(1):103-112. doi: 10.1007/s13167-017-0125-3. eCollection 2018 Mar. EPMA J. 2018. PMID: 29515690 Free PMC article.
Since Central-Eastern European attitude toward genetic testing, especially broad genetic testing, is not well known, we performed a survey on this issue among Hungarian participants. ...RELEVANCE OF THE ARTICLE FOR PREDICTIVE PREVENTIVE AND PERSONAL
Since Central-Eastern European attitude toward genetic testing, especially broad genetic testing, is not well kn …
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Paller CJ, et al. Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18. Clin Genitourin Cancer. 2019. PMID: 31171481 Free PMC article. Clinical Trial.
BACKGROUND: Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. ...CONCLUSION: Joint efforts by urologists, oncologists, genetics counselors, insurers, and cancer centers can acc …
BACKGROUND: Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for …
Evidence and resources to implement pharmacogenetic knowledge for precision medicine.
Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Caudle KE, et al. Am J Health Syst Pharm. 2016 Dec 1;73(23):1977-1985. doi: 10.2146/ajhp150977. Am J Health Syst Pharm. 2016. PMID: 27864205 Free PMC article. Review.
One factor that has inhibited the adoption of genetic data to guide medication use is a lack of knowledge of how to translate genetic test results into clinical action based on currently available evidence. Other implementation challenges include contr …
One factor that has inhibited the adoption of genetic data to guide medication use is a lack of knowledge of how to translate …
Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.
Bush WS, Cooke Bailey JN, Beno MF, Crawford DC. Bush WS, et al. Public Health Genomics. 2019;22(1-2):16-24. doi: 10.1159/000501974. Epub 2019 Aug 27. Public Health Genomics. 2019. PMID: 31454805 Free article. Review.
Despite monumental advances in genomics, relatively few health care provider organizations in the United States offer personalized or precision medicine as part of the routine clinical workflow. ...The limited value assessment in both the research and impl
Despite monumental advances in genomics, relatively few health care provider organizations in the United States offer personalized or …
The role of pharmacogenomics in adverse drug reactions.
Cacabelos R, Cacabelos N, Carril JC. Cacabelos R, et al. Expert Rev Clin Pharmacol. 2019 May;12(5):407-442. doi: 10.1080/17512433.2019.1597706. Epub 2019 Apr 24. Expert Rev Clin Pharmacol. 2019. PMID: 30916581 Review.
Educational programs are fundamental for drug prescribers to become familiar with personalized treatments. Pharmacogenetic testing should be gradually introduced into medical practice. ADRs can be reduced not only by adherence to prescribing guidelines, suitable mon …
Educational programs are fundamental for drug prescribers to become familiar with personalized treatments. Pharmacogenetic testing
Implementation and utilization of the molecular tumor board to guide precision medicine.
Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES. Harada S, et al. Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915716 Free PMC article. Review.
The objective of this report is to analyze our progress to date and discuss the importance of the MTB in the implementation of personalized medicine. ...The application of precision medicine and molecular genetic testing for cancer …
The objective of this report is to analyze our progress to date and discuss the importance of the MTB in the implementation of per
Clinical implementation of genetic testing in medicine: a US regulatory science perspective.
Lesko LJ, Schmidt S. Lesko LJ, et al. Br J Clin Pharmacol. 2014 Apr;77(4):606-11. doi: 10.1111/bcp.12299. Br J Clin Pharmacol. 2014. PMID: 24286486 Free PMC article.
Over the past decade, regulatory agencies realized that they needed to be proactive and not reactive if personalized medicine was to become a reality. ...The following two major approaches to personalized medicine were taken: (i) encouragement of de no …
Over the past decade, regulatory agencies realized that they needed to be proactive and not reactive if personalized medicine
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network. Cavallari LH, et al. JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1. JACC Cardiovasc Interv. 2018. PMID: 29102571 Free PMC article. Clinical Trial.
OBJECTIVES: This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI). ...CONCLUSIONS: These data from real-world observations demonstra …
OBJECTIVES: This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided a …
116 results
Jump to page
Feedback